卡维地洛联合曲美他嗪辅助治疗慢性充血性心力衰竭疗效观察被引量：11

Effect of Combination of Carvedilol and Trimetazidine on Patients with Chronic Congestive Heart Failure

在线阅读下载PDF

导出

摘要目的观察卡维地洛联合曲美他嗪治疗慢性充血性心力衰竭(CHF)的临床疗效。方法选择慢性CHF患者60例,随机分为两组:对照组30例,给予洋地黄制剂、利尿剂、血管扩张剂、血管紧张素转换酶抑制剂(ACEI)等常规药物治疗;治疗组30例,在常规药物治疗基础上加用卡维地洛(2次/d,25mg/次,疗程60d)和曲美他嗪(3次/d,20mg/次,疗程60d)。结果治疗组心功能改善有效率为90.0%,明显高于对照组的60.0%(P<0.01)。治疗前后相比,治疗组心率、血压、左室射血分数、左室舒张末期容积、左室收缩末期容积均有显著改善(P<0.01或P<0.05),治疗组与对照组比较差异有统计学意义(P<0.01或P<0.05)。结论用卡维地洛和曲美他嗪辅助治疗慢性CHF是一种安全有效的方法。 Objective To explore the clinical effect of combination of carvedilol and trimetazidine on chronic congestive heart failure （CHF）. Methods Sixty patients with CHF were divided into two groups randomly. In control group,30 patients were treated with routine medicine, such as digitalis, diuretic agent, vasodilating agent, angiotensin converting enzyme inhibitor （ACEI） ,etc. Thirty patients in treatment group were added with carvedilol and trimetazidine. Results The response rate was 90.0% in treatment group, much higher than that of 60.0% in control group （ P 〈 0.01 ）, Compared with which before treatment, there were much improvements in the heart rate, blood pressure, left ventricular ejection fraction, left ventricular end diastolic volume and left ventricular end-systolic volume in treatment group （P 〈 0.01 or P 〈 0.05 ）, and the differences between the two groups were statistically significant （ P 〈 0.01 or P 〈 0.05 ）. Conclusions It is a safe and effective method in treating chronic CHF with combination of carvedilol and trimetazidine.

作者肖广新陈东成龙信聪

机构地区广东省广州市白云区第二人民医院心内科

出处《实用全科医学》 2007年第3期230-231,共2页 Applied Journal Of General Practice

关键词心力衰竭充血性慢性卡维地洛曲美他嗪 Chronic congestive heart failure Carvedilol Trimetazidine

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1杨田,翟健,庄晓萌,赵仙先.卡维地洛与美托洛尔治疗心力衰竭的对比研究进展[J].心血管病学进展,2003,24(2):105-107. 被引量：12
2王开贞,徐红.β受体阻滞剂在心力衰竭中的应用[J].中国医刊,2002,37(2):51-52. 被引量：18

二级参考文献19

1[1]Denniss AR,March JD,Quigg RT,et al. β-adrenergic receptor member and adenylate cyclase function in denervanted transplanted and cardiomyopathic humen heart[ J ]. Circulation, 1989,79:1028.
2[2]Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition:problems and prospects [J]. Physiol Res, 1999,48 ( 1 ): 1-8.
3[3]Bristow M R. Carvedilol treatment of chronic heart failure: a new era [J]. Heart,1998,79(2) :8.
4[4]Bristow MR. Mechanism of action of beta-blocking agents in heart failure [J].Am J Cardiol,1997,80(11A) :26.
5[5]Gilbert EM, Abraham WT,Olsen S,et al. Comparative hemodynanic,left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart [ J ]. Circulation, 1996.94:2817.
6[6]Stoschitzky K,Koshucharova G,Zweiker R,et al. Differing beta-blocking effects of carvedilol and metoprolol [ J ]. Heart Failure 2001,3 ( 3 ) :343-349.
7[7]Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fration in heart fail:results of a metaanalysis[J]. Heart,2001,141 (6) :899-907.
8[8]Atumanayagam M ,Chan S,Tong S. et al. Antioxidaot peoperties of carvedilol and metoprolol in heart failure:a double-blind randomized controlled trial, [J]. Cardiovasc pharmacol,2001,37( 1 ) :48-54.
9[9]Packer M, Bristow RW, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure [J]. N Engl J Med, 1996,334:1349-1355.
10[10]Bristow MR,Gilbert EM,Abrahan WT,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [ J ]. Circulation, 1996,94: 2708 -2716.